These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30836152)

  • 1. Glabridin smartPearls - Silica selection, production, amorphous stability and enhanced solubility.
    Hespeler D; Kaltenbach J; Pyo SM
    Int J Pharm; 2019 Apr; 561():228-235. PubMed ID: 30836152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermal smartPearls - Optimized silica particles for commercial products & mechanistic considerations.
    Hespeler D; Pyo SM; Müller RH
    Int J Pharm; 2020 Jan; 574():118757. PubMed ID: 31715366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. smartPearls - Novel physically stable amorphous delivery system for poorly soluble dermal actives.
    Müller RH; Hespeler D; Jin N; Pyo SM
    Int J Pharm; 2019 Jan; 555():314-321. PubMed ID: 30439490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral hesperidin-Amorphization and improved dissolution properties by controlled loading onto porous silica.
    Wei Q; Keck CM; Müller RH
    Int J Pharm; 2017 Feb; 518(1-2):253-263. PubMed ID: 27871833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced penetration and anti-psoriatic efficacy of curcumin by improved smartPearls technology with the addition of glycyrrhizic acid.
    Jin N; Lin J; Yang C; Wu C; He J; Chen Z; Yang Q; Chen J; Zheng G; Lv L; Liang H; Chen J; Ruan Z
    Int J Pharm; 2020 Mar; 578():119101. PubMed ID: 32006622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glabridin nanosuspension for enhanced skin penetration: formulation optimization, in vitro and in vivo evaluation.
    Wang WP; Hul J; Sui H; Zhao YS; Feng J; Liu C
    Pharmazie; 2016 May; 71(5):252-7. PubMed ID: 27348968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoporous smartPearls for dermal application - Identification of optimal silica types and a scalable production process as prerequisites for marketed products.
    Hespeler D; El Nomeiri S; Kaltenbach J; Müller RH
    Beilstein J Nanotechnol; 2019; 10():1666-1678. PubMed ID: 31467828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing glabridin stability.
    Ao M; Shi Y; Cui Y; Guo W; Wang J; Yu L
    Nat Prod Commun; 2010 Dec; 5(12):1907-12. PubMed ID: 21299118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and tableting of long-term stable amorphous rutin using porous silica.
    Wei Q; Keck CM; Müller RH
    Eur J Pharm Biopharm; 2017 Apr; 113():97-107. PubMed ID: 27847275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. smartPearls
    Hespeler D; Knoth D; Keck CM; Müller RH; Pyo SM
    Int J Pharm; 2019 May; 562():293-302. PubMed ID: 30853483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
    Li T; Geng T; Md A; Banerjee P; Wang B
    Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced skin permeation of glabridin using eutectic mixture-based nanoemulsion.
    Liu C; Hu J; Sui H; Zhao Q; Zhang X; Wang W
    Drug Deliv Transl Res; 2017 Apr; 7(2):325-332. PubMed ID: 28188607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular-level insight into hot-melt loading and drug release from mesoporous silica carriers.
    Lizoňová D; Mužík J; Šoltys M; Beránek J; Kazarian SG; Štěpánek F
    Eur J Pharm Biopharm; 2018 Sep; 130():327-335. PubMed ID: 30012403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review on the Diverse Biological Effects of Glabridin.
    Zhang J; Wu X; Zhong B; Liao Q; Wang X; Xie Y; He X
    Drug Des Devel Ther; 2023; 17():15-37. PubMed ID: 36647530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facile large-scale preparation of mesoporous silica microspheres with the assistance of sucrose and their drug loading and releasing properties.
    Bi Y; Wu C; Xin M; Bi S; Yan C; Hao J; Li F; Li S
    Int J Pharm; 2016 Mar; 500(1-2):77-84. PubMed ID: 26784977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of HPLC and HPTLC Methods for Estimation of Glabridin in Extracts of Glycyrrhiza glabra.
    Viswanathan V; Mukne AP
    J AOAC Int; 2016; 99(2):374-9. PubMed ID: 27103104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method.
    Yang G; Li Z; Wu F; Chen M; Wang R; Zhu H; Li Q; Yuan Y
    Int J Nanomedicine; 2020; 15():1661-1675. PubMed ID: 32210559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced dissolution of valsartan-vanillin binary co-amorphous system loaded in mesoporous silica particles.
    Hashim Ali K; Mohsin Ansari M; Ali Shah F; Ud Din F; Abdul Basit M; Kim JK; Zeb A
    J Microencapsul; 2019 Jan; 36(1):10-20. PubMed ID: 30719944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization.
    Abd-Elrahman AA; El Nabarawi MA; Hassan DH; Taha AA
    Drug Deliv; 2016 Nov; 23(9):3387-3398. PubMed ID: 27167529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
    Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
    Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.